Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3761-3770 Newer>

BusinessWeek June 11, 2007 Catherine Arnst	The Right Cure For Ailing Elder Care? Nurse practitioners could save the nation money - while providing quality service.
BusinessWeek June 11, 2007 Mara Der Hovanesian	Why Seprecor May Surprise The Naysayers Sentiment is mixed on Wall Street about Sepracor, the Marlborough pharmaceutical best known for its sleep drug, Lunesta.
The Motley Fool May 31, 2007 Billy Fisher	Not Seeing 20/20 at Advanced Medical Optics The company recalls a contact lens solution that might be linked to a rare infection. Investors, take note.
The Motley Fool May 31, 2007 Brian Lawler	Bad Alkermes? The drug-delivery expert releases financial results and includes a little negative surprise for investors.
The Motley Fool May 31, 2007 Brian Lawler	Bradley Offers to Buy Itself The drugmaker's CEO offers to take the company private. But are all buyout offers a good deal for shareholders?
The Motley Fool May 31, 2007 Tim Beyers	Biogen's $3 Billion Bet There are times when a buyback is not only appropriate, but also smart. This is one of those times for Biogen Idec. It's a chance for management to deliver huge returns to long-suffering shareholders.
Chemistry World June 2007 Derek Lowe	Opinion: In the Pipeline A medicinal chemist experienced in pre-clinical drug discovery sets the record straight about pharmaceutical patents on traditional medicines.
Chemistry World May 30, 2007 Hepeng Jia	Disgraced Drug Chief Sentenced to Death As China battles to root out corruption from its pharmaceutical sector, the former head of the State Food and Drug Agency, Zheng Xiaoyu, has been sentenced to death after being found guilty of taking bribes.
HBS Working Knowledge May 30, 2007 Sean Silverthorne	Health Care Under a Research Microscope The $2 trillion American health care system has grown bloated and overly expensive, and it delivers poor service to many patients. Harvard Business School faculty are looking at the system through a business management perspective to recommend changes.
The Motley Fool May 30, 2007 Brian Orelli	MedImmune's FDA Roller Coaster The vaccine maker is having its share of ups and downs, courtesy of the FDA. Investors, take note.
<Older 3761-3770 Newer> Return to current articles.